{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:49:45Z","timestamp":1787993385145,"version":"build-2784847793"},"reference-count":153,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adolescents and young adults (AYAs) with relapsed\/refractory acute lymphoblastic leukemia (ALL) face unique challenges as they experience greater treatment resistance, higher rates of toxicity, and present at a specific life stage with distinct priorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support clinicians, patients, and other health care professionals in their decisions about management of AYAs with relapsed\/refractory ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ASH formed a multidisciplinary guideline panel including hematologists, AYA psychosocial care specialists, pharmacists, methodologists, and patient representatives with efforts to minimize bias from conflicts of interest. An evidence review team at Brown University supported guideline development, including performing systematic evidence reviews up to November 2023. The panel prioritized clinical questions and outcomes according to importance for clinicians and patients. The panel used Grading of Recommendations Assessment, Development and Evaluation (GRADE), including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panel agreed on 8 recommendations and 1 research-only recommendation, covering remission reinduction and consolidation. They focused on the following treatment modalities: immunotherapy, targeted therapies, allogeneic hematopoietic stem cell transplant, and central nervous system (CNS)\u2013directed therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Key recommendations include the use of blinatumomab and\/or inotuzumab over chemotherapy for reinduction. Additional management of ALL subsets (T-cell ALL), CNS relapse, and the role of consolidation with allogeneic transplant are addressed. Future research should evaluate these approaches with special attention to the unique AYA population, and should evaluate quality of life outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2021006479","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:56:00Z","timestamp":1770825360000},"page":"4726-4756","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["American Society of Hematology 2026 guidelines for management of relapsed\/refractory acute lymphoblastic leukemia in adolescents and young adults"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-8198","authenticated-orcid":false,"given":"Kristen","family":"O\u2019Dwyer","sequence":"first","affiliation":[{"name":"1Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-1594","authenticated-orcid":false,"given":"Lena E.","family":"Winestone","sequence":"additional","affiliation":[{"name":"2Division of Allergy, Immunology, and Blood & Marrow Transplant, University of California, San Francisco Benioff Children\u2019s Hospitals, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3193-5872","authenticated-orcid":false,"given":"Matthew C.","family":"Cheung","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Benitez","sequence":"additional","affiliation":[{"name":"4Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[{"name":"5Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, Padua University, Padua, Italy"},{"name":"6Pediatric Onco-Hematology, Stem Cell Transplant and Gene Therapy Laboratory, Istituto di Ricerca Pediatrica, Citt\u00e0 della Speranza, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3525-8015","authenticated-orcid":false,"given":"Peter D.","family":"Cole","sequence":"additional","affiliation":[{"name":"7Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussab","family":"Damlaj","sequence":"additional","affiliation":[{"name":"8Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"9Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoy L.","family":"Dias","sequence":"additional","affiliation":[{"name":"10Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-4726","authenticated-orcid":false,"given":"Alexander","family":"Dils","sequence":"additional","affiliation":[{"name":"11Department of Internal Medicine, University of Michigan Medicine, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fritsch","sequence":"additional","affiliation":[{"name":"12Texas Children\u2019s Cancer and Hematology Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Greer","sequence":"additional","affiliation":[{"name":"9Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-4573","authenticated-orcid":false,"given":"Brandon","family":"Hayes-Lattin","sequence":"additional","affiliation":[{"name":"13Oregon Health and Science University Knight Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meret","family":"Henry","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology\/Bone Marrow Transplantation, Department of Pediatrics, Children\u2019s Hospital of Michigan, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Jaffe","sequence":"additional","affiliation":[{"name":"15Halethorpe, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"17The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5094-3468","authenticated-orcid":false,"given":"Ilayna","family":"Mehrtens","sequence":"additional","affiliation":[{"name":"18Biological Sciences Division, Department of Psychiatry and Behavioral Neuroscience, Section of Child and Adolescent Psychiatry, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"19Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Wilde","sequence":"additional","affiliation":[{"name":"20Division of Hematologic Malignancies, Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2161-9377","authenticated-orcid":false,"given":"Patricia A.","family":"Young","sequence":"additional","affiliation":[{"name":"21Division of Hematology\/Oncology, Department of Medicine, University of California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1357-1088","authenticated-orcid":false,"given":"Htun Ja","family":"Mai","sequence":"additional","affiliation":[{"name":"22Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghid","family":"Kanaan","sequence":"additional","affiliation":[{"name":"22Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4017-4561","authenticated-orcid":false,"given":"Yuliia","family":"Sereda","sequence":"additional","affiliation":[{"name":"22Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2062-3382","authenticated-orcid":false,"given":"Ian J.","family":"Saldanha","sequence":"additional","affiliation":[{"name":"23Center for Clinical Trials and Evidence Synthesis, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4376-7290","authenticated-orcid":false,"given":"Ethan M.","family":"Balk","sequence":"additional","affiliation":[{"name":"22Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-3670","authenticated-orcid":false,"given":"Sumit","family":"Gupta","sequence":"additional","affiliation":[{"name":"24Division of Hematology\/Oncology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2026071409564844300_bib1","author":"Institute of Medicine","year":"2011"},{"issue":"7","key":"2026071409564844300_bib2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-156-7-201204030-00009","article-title":"Guidelines International Network: toward international standards for clinical practice guidelines","volume":"156","author":"Qaseem","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7","key":"2026071409564844300_bib3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.7326\/M14-1885","article-title":"Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines","volume":"163","author":"Schunemann","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026071409564844300_bib4","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"2026071409564844300_bib5","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"2026071409564844300_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"2026071409564844300_bib7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"2026071409564844300_bib8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"2026071409564844300_bib9","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Schunemann","year":"2003","journal-title":"CMAJ"},{"key":"2026071409564844300_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jclinepi.2016.01.032","article-title":"GRADE guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health","volume":"76","author":"Schunemann","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026071409564844300_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jclinepi.2016.07.006","article-title":"Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group","volume":"80","author":"Guyatt","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026071409564844300_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2021.09.028","article-title":"A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations","volume":"141","author":"Lotfi","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2026071409564844300_bib13","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1503\/cmaj.131237","article-title":"Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise","volume":"186","author":"Schunemann","year":"2014","journal-title":"CMAJ"},{"key":"2026071409564844300_bib14","author":"Institute of Medicine","year":"2009"},{"issue":"11","key":"2026071409564844300_bib15","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jclinepi.2014.05.006","article-title":"Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study","volume":"67","author":"Akl","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"2026071409564844300_bib16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-152-11-201006010-00254","article-title":"The vexing problem of guidelines and conflict of interest: a potential solution","volume":"152","author":"Guyatt","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2026071409564844300_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.200901-0126ST","article-title":"An official American Thoracic Society policy statement: managing conflict of interest in professional societies","volume":"180","author":"Schunemann","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026071409564844300_bib152","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2026.100222","article-title":"Prioritized health outcomes for adolescents and young adults with acute leymphoblastic leukemia","author":"Saldanha","year":"26  2026","journal-title":"Blood Neo"},{"key":"2026071409564844300_bib18","unstructured":"Agency for Healthcare Research and Quality\n          . Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Accessed 3 March 2026. https:\/\/effectivehealthcare.ahrq.gov\/products\/collections\/cer-methods-guide."},{"key":"2026071409564844300_bib19","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2026071409564844300_bib20","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"9","key":"2026071409564844300_bib21","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1038\/bcj.2016.84","article-title":"Blinatumomab vs historical standard therapy of adult relapsed\/refractory acute lymphoblastic leukemia","volume":"6","author":"G\u00f6kbuget","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026071409564844300_bib22","first-page":"217","article-title":"Blinatumomab therapy is associated with favorable outcomes after allogeneic hematopoietic cell transplantation in pediatric patients with B cell acute lymphoblastic leukemia","volume":"30","author":"Llaurador","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026071409564844300_bib23","first-page":"255.e1","article-title":"Allogeneic hematopoietic cell transplantation for relapsed and refractory Philadelphia negative B cell ALL in the era of novel salvage therapies","volume":"27","author":"Aldoss","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"36","key":"2026071409564844300_bib24","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026071409564844300_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"36","key":"2026071409564844300_bib26","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026071409564844300_bib27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00280-006-0332-4","article-title":"High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study","volume":"59","author":"Tedeschi","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"2026071409564844300_bib28","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1080\/10428194.2019.1639170","article-title":"Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed Philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol","volume":"60","author":"Bassan","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2026071409564844300_bib29","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00277-006-0121-5","article-title":"Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG)","volume":"85","author":"Giebel","year":"2006","journal-title":"Ann Hematol"},{"key":"2026071409564844300_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.12.022","article-title":"Long-term follow-up of blinatumomab in patients with relapsed\/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study","volume":"146","author":"Martinelli","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026071409564844300_bib31","doi-asserted-by":"crossref","first-page":"20406207231154713","DOI":"10.1177\/20406207231154713","article-title":"Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis","volume":"14","author":"Yoon","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"2026071409564844300_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2026071409564844300_bib33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0145-2126(99)00148-4","article-title":"A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia","volume":"24","author":"Rosen","year":"2000","journal-title":"Leuk Res"},{"issue":"2","key":"2026071409564844300_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.32558","article-title":"Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia","volume":"126","author":"Rambaldi","year":"2020","journal-title":"Cancer"},{"issue":"11","key":"2026071409564844300_bib35","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1007\/s00262-023-03514-3","article-title":"Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19\/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"72","author":"Shimazu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2026071409564844300_bib36","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2026071409564844300_bib37","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","article-title":"Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia","volume":"2","author":"Stein","year":"2018","journal-title":"Blood Adv"},{"issue":"26","key":"2026071409564844300_bib38","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2026071409564844300_bib39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"Jama"},{"issue":"25","key":"2026071409564844300_bib40","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: phase III trial of blinatumomab in children, adolescents, and young adults with low-risk B-cell ALL in first relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026071409564844300_bib41","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2026071409564844300_bib42","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"2026071409564844300_bib43","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2022-166234","article-title":"ALL-REZ BFM 2002 is associated with improved outcome as compared to ALL-R3 strategy in children with standard risk isolated CNS relapse of acute lymphoblastic leukemia, while maintaining comparable efficacy in patients with bone marrow relapse. Results of the multi-national, multi-center trial IntReALL SR 2010 [abstract]","volume":"140","author":"Von Stackelberg","year":"2022","journal-title":"Blood"},{"issue":"9757","key":"2026071409564844300_bib44","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"2026071409564844300_bib45","doi-asserted-by":"crossref","first-page":"804714","DOI":"10.3389\/fonc.2021.804714","article-title":"Real-world multicenter experience in tumor debulking prior to blinatumomab administration in adult patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"11","author":"Bonifacio","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"2026071409564844300_bib46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12874-023-01895-8","article-title":"Strong recommendations from low certainty evidence: a cross-sectional analysis of a suite of national guidelines","volume":"23","author":"Chong","year":"2023","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"2026071409564844300_bib47","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2026071409564844300_bib48","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"issue":"15","key":"2026071409564844300_bib49","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2026071409564844300_bib50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-023-01444-2","article-title":"Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia","volume":"16","author":"Kantarjian","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2026071409564844300_bib51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phstudy","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026071409564844300_bib52","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/cncr.31249","article-title":"Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"2026071409564844300_bib53","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood.2020007848","article-title":"A phase study of inotuzumab ozogamicin in pediatric relapsed\/refractory acute lymphoblastic leukemia (ITCC-059 study)","volume":"137","author":"Brivio","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026071409564844300_bib54","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","article-title":"Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial","volume":"109","author":"Pennesi","year":"2024","journal-title":"Haematologica"},{"issue":"14","key":"2026071409564844300_bib55","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"6","key":"2026071409564844300_bib56","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/cncr.33321","article-title":"Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Stock","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"2026071409564844300_bib57","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phINO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"2026071409564844300_bib58","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"2026071409564844300_bib59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-020-00345-8","article-title":"Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: outcomes by disease burden","volume":"10","author":"DeAngelo","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"2026071409564844300_bib60","first-page":"946","article-title":"Targeted immunotherapy efficacy analysis in patients with relapsed\/refractory B cell acute lymphocytic leukemia","volume":"43","author":"Su","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"5","key":"2026071409564844300_bib61","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00277-018-3246-4","article-title":"CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory\/relapsed acute lymphoblastic leukemia: results of a case-controlled study","volume":"97","author":"Wei","year":"2018","journal-title":"Ann Hematol"},{"issue":"12","key":"2026071409564844300_bib62","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2026071409564844300_bib63","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026071409564844300_bib64","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2026071409564844300_bib65","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2026071409564844300_bib66","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/bjh.18105","article-title":"Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia","volume":"197","author":"Jacoby","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"2026071409564844300_bib67","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026071409564844300_bib68","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026071409564844300_bib69","doi-asserted-by":"crossref","first-page":"e002287","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"16","key":"2026071409564844300_bib70","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2026071409564844300_bib71","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"2026071409564844300_bib72","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2026071409564844300_bib73","doi-asserted-by":"crossref","first-page":"e007118","DOI":"10.1136\/jitc-2023-007118","article-title":"Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"11","author":"Shah","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2026071409564844300_bib74","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"2026071409564844300_bib75","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026071409564844300_bib76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","article-title":"Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: a multi-center retrospective study","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2026071409564844300_bib77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16623","article-title":"Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory\/relapsed B acute lymphoblastic leukaemia","volume":"191","author":"Wang","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2026071409564844300_bib78","first-page":"557","article-title":"Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"43","author":"Wang","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"27","key":"2026071409564844300_bib79","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10299","key":"2026071409564844300_bib80","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"2026071409564844300_bib81","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"2026071409564844300_bib82","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026071409564844300_bib83","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026071409564844300_bib84","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1038\/s41467-020-19774-x","article-title":"Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia","volume":"11","author":"An","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"2026071409564844300_bib85","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026071409564844300_bib86","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026071409564844300_bib87","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2026071409564844300_bib88","first-page":"21","article-title":"Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic lymphoma remission confers a leukemia-free survival advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"2026071409564844300_bib89","doi-asserted-by":"crossref","first-page":"605766","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"2026071409564844300_bib90","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1007\/s12325-023-02662-3","article-title":"Matching-adjusted indirect comparisons of brexucabtagene autoleucel with alternative standard therapies for relapsed\/refractory B-cell acute lymphoblastic leukemia in adult patients","volume":"40","author":"Shah","year":"2023","journal-title":"Adv Ther"},{"issue":"1","key":"2026071409564844300_bib91","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.16339","article-title":"Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory\/ relapsed B-cell acute lymphomalastic leukemia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2026071409564844300_bib92","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"2026071409564844300_bib93","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"Gokbuget","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"2026071409564844300_bib94","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"21","key":"2026071409564844300_bib95","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","article-title":"Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group","volume":"31","author":"Eckert","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9289","key":"2026071409564844300_bib96","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0140-6736(01)06355-3","article-title":"Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia","volume":"358","author":"Eckert","year":"2001","journal-title":"Lancet"},{"issue":"24","key":"2026071409564844300_bib97","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study[corrected]","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026071409564844300_bib98","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.bmt.1705769","article-title":"Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study","volume":"40","author":"Gutierrez-Aguirre","year":"2007","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"2026071409564844300_bib99","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2352-3026(19)30003-1","article-title":"Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial","volume":"6","author":"Parker","year":"2019","journal-title":"Lancet Haematol"},{"issue":"6","key":"2026071409564844300_bib100","first-page":"326.e1","article-title":"Allogeneic hematopoietic stem cell transplantation for adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in second complete remission","volume":"28","author":"Kaito","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"17","key":"2026071409564844300_bib101","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","article-title":"Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the bone marrow transplant survivor study","volume":"116","author":"Sun","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2026071409564844300_bib102","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2026071409564844300_bib103","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026071409564844300_bib104","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.22.00767","article-title":"Busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for adults acute B lymphoblastic leukemia: an open-label, multicenter, phase III trial","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026071409564844300_bib105","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","article-title":"Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia","volume":"24","author":"Kebriaei","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026071409564844300_bib106","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/bmt.2010.314","article-title":"BU- vs TBI-based conditioning for adult patients with ALL","volume":"46","author":"Kalaycio","year":"2011","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2026071409564844300_bib107","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.3109\/10428194.2013.779691","article-title":"Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant","volume":"54","author":"Eroglu","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2026071409564844300_bib108","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00277-018-3383-9","article-title":"Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study","volume":"97","author":"Sakellari","year":"2018","journal-title":"Ann Hematol"},{"issue":"3","key":"2026071409564844300_bib109","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/bmt.2015.278","article-title":"Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"51","author":"Cahu","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2026071409564844300_bib110","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.24823","article-title":"Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: a matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"92","author":"Eder","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"2026071409564844300_bib111","first-page":"171.e1","article-title":"Improved outcomes of haploidentical hematopoietic cell transplantation with total body irradiation-based myeloablative conditioning in acute lymphoblastic leukemia","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"2026071409564844300_bib112","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.bbmt.2016.09.007","article-title":"Comparison of cyclophosphamide combined with total body irradiation, oral busulfan, or intravenous busulfan for allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia","volume":"22","author":"Mitsuhashi","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2026071409564844300_bib113","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.bbmt.2012.06.010","article-title":"Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Kebriaei","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"26","key":"2026071409564844300_bib114","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.2018874115","article-title":"Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation","volume":"133","author":"Baker","year":"2019","journal-title":"Blood"},{"issue":"22","key":"2026071409564844300_bib115","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2026071409564844300_bib116","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026071409564844300_bib117","doi-asserted-by":"crossref","first-page":"e28079","DOI":"10.1002\/pbc.28079","article-title":"The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"67","author":"Friend","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"24","key":"2026071409564844300_bib118","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood.2022015959","article-title":"KIR-favorable TCR-\u03b1\u03b2\/CD19-depleted haploidentical HCT in children with ALL\/AML\/MDS: primary analysis of the PTCTC ONC1401 trial","volume":"140","author":"Pulsipher","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026071409564844300_bib119","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjh.18537","article-title":"Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: a retrospective multicentre Campus ALL study","volume":"200","author":"Dargenio","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2026071409564844300_bib120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.bbmt.2017.11.013","article-title":"Augmenting total body irradiation with a cranial boost before stem cell transplantation protects against post-transplant central nervous system relapse in acute lymphoblastic leukemia","volume":"24","author":"Gao","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2026071409564844300_bib121","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"issue":"19","key":"2026071409564844300_bib122","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.2005.03.3373","article-title":"Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study","volume":"24","author":"Barredo","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026071409564844300_bib123","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/bloodadvances.2024015779","article-title":"Outcomes of brexucabtagene autoleucel in patients with relapsed\/refractory acute lymphoblastic leukemia patients with CNS involvement","volume":"9","author":"Muhsen","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"2026071409564844300_bib124","first-page":"S7","article-title":"Assessment of central nervous system responses in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia receiving brexucabtagene autoleucel as an FDA-approved standard of care","volume":"30","author":"Muhsen","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"21","key":"2026071409564844300_bib125","first-page":"2237","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): results from the phDELPHINUS study","volume":"144","author":"Hogan","year":"2022","journal-title":"ASCO"},{"issue":"19","key":"2026071409564844300_bib126","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.22.02734","article-title":"The clinicogenomic landscape of induction failure in childhood and young adult T-cell acute lymphoblastic leukemia","volume":"41","author":"O'Connor","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026071409564844300_bib127","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026071409564844300_bib128","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2026071409564844300_bib129","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"G\u00f6kbuget","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2026071409564844300_bib130","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bjh.14874","article-title":"Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phstudy","volume":"179","author":"Zwaan","year":"2017","journal-title":"Br J Haematol"},{"issue":"28","key":"2026071409564844300_bib131","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026071409564844300_bib132","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"key":"2026071409564844300_bib133","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2021.03.034","article-title":"Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials","volume":"151","author":"Eckert","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"2026071409564844300_bib134","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ajh.25957","article-title":"Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study","volume":"95","author":"Candoni","year":"2020","journal-title":"Am J Hematol"},{"key":"2026071409564844300_bib153","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006469","article-title":"American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults","author":"DuVall","year":"11  2026","journal-title":"Blood Adv"},{"issue":"21","key":"2026071409564844300_bib135","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1182\/bloodadvances.2023011481","article-title":"ASH clinical practice guidelines: strategies to stay up-to-date","volume":"7","author":"Cheung","year":"2023","journal-title":"Blood Adv"},{"key":"2026071409564844300_bib136","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT","volume":"81","author":"Schunemann","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2026071409564844300_bib137","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jayao.2021.0012","article-title":"Technology-assisted psychosocial interventions for childhood, adolescent, and young adult cancer survivors: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2022","journal-title":"J Adolesc Young Adult Oncol"},{"key":"2026071409564844300_bib138","doi-asserted-by":"crossref","first-page":"103291","DOI":"10.1016\/j.critrevonc.2021.103291","article-title":"Psychosocial, behavioral, and supportive interventions for pediatric, adolescent, and young adult cancer survivors: a systematic review and meta-analysis","volume":"160","author":"Zhang","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026071409564844300_bib139","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/978-3-540-68152-6_24","volume-title":"Cancer in Adolescents And Young Adults","author":"Zebrack","year":"2007","edition":"1st ed"},{"issue":"9","key":"2026071409564844300_bib140","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.6004\/jnccn.2012.0117","article-title":"Adolescent and young adult oncology. Clinical practice guidelines in oncology","volume":"10","author":"Coccia","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"2026071409564844300_bib141","first-page":"167","article-title":"Distress and adjustment among adolescents and young adults with cancer: an empirical and conceptual review","volume":"2","author":"Sansom-Daly","year":"2013","journal-title":"Transl Pediatr"},{"issue":"7","key":"2026071409564844300_bib142","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/cncr.35180","article-title":"Resilience in adolescent and young adult oncology: problems and prospects","volume":"130","author":"Rosenberg","year":"2024","journal-title":"Cancer"},{"issue":"17","key":"2026071409564844300_bib143","doi-asserted-by":"crossref","first-page":"18354","DOI":"10.1002\/cam4.6435","article-title":"Prevalence and risk of psychological distress, anxiety and depression in adolescent and young adult (AYA) cancer survivors: a systematic review and meta-analysis","volume":"12","author":"Osmani","year":"2023","journal-title":"Cancer Med"},{"issue":"11","key":"2026071409564844300_bib144","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2011.39.5467","article-title":"Psychosocial care of adolescent and young adult patients with cancer and survivors","volume":"30","author":"Zebrack","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026071409564844300_bib145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/PROM.S51658","article-title":"Quality of life in adolescent and young adult cancer patients: a systematic review of the literature","volume":"6","author":"Quinn","year":"2015","journal-title":"Patient Relat Outcome Meas"},{"issue":"8","key":"2026071409564844300_bib146","doi-asserted-by":"crossref","first-page":"e27789","DOI":"10.1002\/pbc.27789","article-title":"Psychosocial issues for adolescent and young adult cancer patients in a global context: a forward-looking approach","volume":"66","author":"Levin","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026071409564844300_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jayao.2017.0040","article-title":"Post-traumatic growth and resilience in adolescent and young adult cancer patients: an overview","volume":"7","author":"Greup","year":"2018","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"5","key":"2026071409564844300_bib148","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3390\/jcm9051444","article-title":"The needs and experiences of post-treatment adolescent and young adult cancer survivors","volume":"9","author":"Jones","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"2026071409564844300_bib149","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.23.01027","article-title":"Access to care for adolescents and young adults with cancer in the United States: state of the literature","volume":"42","author":"Kirchhoff","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026071409564844300_bib150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/jayao.2023.0056","article-title":"Gaps in adolescent and young adult cancer education in oncology fellowship training","volume":"13","author":"Moerdler","year":"2024","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"15","key":"2026071409564844300_bib151","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1002\/cam4.4077","article-title":"Pediatric oncology clinician communication about sexual health with adolescents and young adults: a report from the Children's Oncology Group","volume":"10","author":"Frederick","year":"2021","journal-title":"Cancer Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4726\/2531270\/blooda_adv-2021-006479-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4726\/2531270\/blooda_adv-2021-006479-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:57:11Z","timestamp":1784037431000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4726\/566562\/American-Society-of-Hematology-2026-guidelines-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":153,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006479","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,30]]}}}